HB9090, titled the Advancing Menopause Care and Mid-Life Women’s Health Act, would create a broad federal initiative to improve research, education, training, and care delivery related to perimenopause, menopause, and postmenopause. The bill directs the National Institutes of Health and the Department of Health and Human Services to expand research on the physical, mental, cognitive, oral, and behavioral health effects of menopause, including related chronic conditions such as osteoporosis, cardiovascular disease, sleep disorders, pelvic floor disorders, and mood disorders. It also calls for new data categories, a public dashboard, interagency coordination, and annual reporting to Congress on progress, barriers, and disparities.
The bill further establishes public health promotion, awareness, and outreach programs, including a national education campaign, a website with accessible materials, and targeted outreach to patients, providers, first responders, and underserved communities. It authorizes grants for training programs for health professionals, including residency and fellowship programs, and creates Centers of Excellence in Menopause and Mid-Life Women’s Health to develop and distribute evidence-based resources. The legislation also emphasizes care coordination, early detection, quality improvement, mental health and substance use services, and evaluation of new treatments and diagnostic tools, including AI-enabled devices.
In terms of state and federal policy impact, HB9090 would amend the Public Health Service Act to add new federal research, grant, and outreach authorities, but it does not directly change state law. Its practical effect would be to steer federal funding and guidance toward menopause-related research and care, with grants available to state, local, Tribal, and territorial public health departments, health professional schools, hospitals, and research institutions. The bill authorizes appropriations of $25 million annually for research and data activities and $10 million annually each for public health promotion, outreach, and training, with additional sums authorized for centers of excellence and reporting.
The available context shows no committee transcript, no recorded votes, and no formal opposition or support statements, so the overall sentiment cannot be measured from debate history. Based on the text alone, the bill appears strongly supportive of expanding attention to women’s mid-life health and addressing gaps in diagnosis, treatment, and provider training. The emphasis on disparities, rural access, and underserved populations suggests a public health framing rather than a partisan or regulatory one.
Notable potential points of contention are likely to involve federal spending, the scope of NIH and HHS responsibilities, and whether the bill duplicates or overlaps existing women’s health, aging, or public health programs. Some stakeholders may also question the bill’s broad treatment of menopause-related conditions, the use of federal reporting and dashboards, or the inclusion of oversight for new diagnostic tools and AI-based devices. However, no specific objections are documented in the provided materials.
HB9090 would amend the Public Health Service Act to create new federal research, grant, outreach, training, and reporting programs focused on menopause and mid-life women’s health. It would direct NIH and HHS to expand research, establish public health campaigns, fund training and centers of excellence, and report annually to Congress. The bill does not directly alter state statutes, but it would affect state and local public health departments, health professional schools, hospitals, and research institutions that may seek federal grants or participate in federally coordinated programs.
The bill’s text reflects a strongly supportive policy approach toward improving menopause care, expanding research, and reducing disparities in access and treatment. Because no committee transcript or vote history is provided, there is no documented floor or committee sentiment to gauge beyond the bill’s own framing. On its face, the measure appears to have a public health and women’s health consensus orientation, with no recorded opposition in the supplied materials.
No specific points of contention are documented in the provided transcripts or votes, because none were supplied. Potential areas of debate inferred from the bill text include the level of federal spending, whether the new programs duplicate existing HHS or NIH efforts, the breadth of conditions and services covered, and the federal role in setting research priorities, provider training, and oversight of new treatments and AI-enabled diagnostic tools. Any concerns would likely come from fiscal conservatives, skeptics of new federal programs, or stakeholders worried about administrative overlap.